Non-small Cell Lung Cancer
📧 Sign up to get email alerts when something new happens for Non-small Cell Lung Cancer.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS trial_result · 2019-12-13Clinical Trial Update: Study of Pembrolizumab (MK-3475) in Participants With Progressive Locally Advanced or Metastatic Carcinoma, Melanoma, or Non-small Cell Lung Carcinoma (P07990/MK-3475-001/KEYNOTE-001) [Phase 1]
Phase 1 study of pembrolizumab (MK-3475) in participants with progressive locally advanced/metastatic carcinoma, melanoma, or non-small cell…
-
CLINICAL_TRIALS trial_result · 2019-12-10Clinical Trial Update: The Role of Brain Radiotherapy in Patients With Asymptomatic Brain Metastasis in the Era of Targeted Therapy for NSCLC [Phase 2]
A Phase 2 clinical trial evaluating the role of brain radiotherapy in asymptomatic brain metastases in non-small cell lung cancer patients u…
-
CLINICAL_TRIALS trial_result · 2019-12-10Clinical Trial Update: An Exploration of Apatinib Combined With S-1 in Patients With Advanced Non-small Cell Lung Cancer [Phase 2]
Phase 2 clinical trial exploring the combination of apatinib and S-1 in advanced non-small cell lung cancer has completed.
-
CLINICAL_TRIALS trial_result · 2019-12-09Clinical Trial Update: Chemotherapy With Pembrolizumab Continuation After Progression to PD-1/L1 Inhibitors [Phase 2]
A Phase 2 trial investigating continuation of chemotherapy with pembrolizumab after progression on PD-1/PD-L1 inhibitors in metastatic non-s…
-
CLINICAL_TRIALS trial_result · 2019-12-03Clinical Trial Update: Trametinib in Patients With Advanced Neurofibromatosis Type 1 (NF1)-Mutant Non-small Cell Lung Cancer [Phase 2]
Phase 2 trial update of trametinib in patients with NF1-mutant non-small cell lung cancer has been terminated.
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS trial_result · 2019-12-02Clinical Trial Update: Study of Anlotinib Plus Chemoradiotherapy in Patients With Locally Advanced NSCLC [Phase 1, Phase 2]
Phase 1/2 trial evaluating anlotinib in combination with chemoradiotherapy for locally advanced non-small cell lung cancer.
-
CLINICAL_TRIALS trial_result · 2019-11-29Clinical Trial Update: Phase III Open Label First Line Therapy Study of MEDI 4736 (Durvalumab) With or Without Tremelimumab Versus SOC in Non Small-Cell Lung Cancer (NSCLC) [Phase 3]
Phase III open-label study evaluating durvalumab with or without tremelimumab versus standard-of-care in first-line non-small cell lung canc…
-
CLINICAL_TRIALS trial_result · 2019-11-29Clinical Trial Update: A Study of Neoadjuvant Chemotherapy Plus Anlotinib in Stage III(N2) Non-small-cell Lung Cancer [Phase 2]
Phase 2 trial update evaluating neoadjuvant chemotherapy plus anlotinib for Stage III non-small-cell lung cancer.
-
CLINICAL_TRIALS trial_result · 2019-11-29Clinical Trial Update: Single Agent Chemotherapy +/- Nivolumab in Patients With Advanced Squamous or Non-squamous NSCLC With Primary Resistance to Prior PD-1 or PDL-1 Inhibitor [Phase 2]
Phase 2 trial evaluating single agent chemotherapy with or without nivolumab in advanced NSCLC patients with primary resistance to prior PD-…
-
CLINICAL_TRIALS trial_result · 2019-11-27Clinical Trial Update: SRS Sequential Sindilimab in Brain Metastasis of NSLSC [Phase 2]
Phase 2 trial update for sequential sintilimab (SRS) in brain metastases from NSCLC.
-
CLINICAL_TRIALS trial_result · 2019-11-25Clinical Trial Update: A Study of Alectinib in RET-rearranged Non-small Cell Lung Cancer or RET-mutated Thyroid Cancer [Phase 1, Phase 2]
Clinical trial update for alectinib in RET-rearranged non-small cell lung cancer and RET-mutated thyroid cancer; study terminated with resul…
-
CLINICAL_TRIALS trial_result · 2019-11-25Clinical Trial Update: Concordance of Key Actionable Genomic Alterations as Assessed in Tumor Tissue and Plasma in Non Small Cell Lung Cancer
A terminated clinical trial update evaluating concordance of actionable genomic alterations between tumor tissue and plasma in non-small cel…
-
CLINICAL_TRIALS withdrawal · 2019-11-22Clinical Trial Update: Phase III Study of Nazartinib (EGF816) Versus Erlotinib/Gefitinib in First-line Locally Advanced / Metastatic NSCLC With EGFR Activating Mutations [Phase 3]
Phase III trial comparing Nazartinib to Erlotinib/Gefitinib in first-line locally advanced/metastatic non-small cell lung cancer has been wi…
-
CLINICAL_TRIALS trial_result · 2019-11-22Clinical Trial Update: Erlotinib in Women With Previously Untreated Adenocarcinoma of the Lung [Phase 2]
Phase 2 trial update evaluating erlotinib in women with previously untreated adenocarcinoma of the lung.
-
CLINICAL_TRIALS trial_result · 2019-11-22Clinical Trial Update: Study of Combined Ionizing Radiation and Ipilimumab in Metastatic Non-small Cell Lung Cancer (NSCLC) [Phase 1, Phase 2]
Phase 1/2 study evaluating combination of ionizing radiation and ipilimumab in metastatic non-small cell lung cancer has completed with resu…
-
CLINICAL_TRIALS trial_result · 2019-11-22Clinical Trial Update: A Study to Evaluate Camrelizumab in Combination With Nb-Paclitaxel in Patients With Advanced or Metastatic NSCLC [Phase 2]
Phase 2 trial evaluating camrelizumab in combination with Nb-paclitaxel for advanced or metastatic non-small cell lung cancer.
-
CLINICAL_TRIALS trial_result · 2019-11-22Clinical Trial Update: Rapid Plasma Genotyping For Early Initiation Of Erlotinib In EGFR Mutant Lung Cancer [Phase 2]
Phase 2 trial evaluating rapid plasma genotyping to initiate erlotinib early in EGFR-mutant non-small cell lung cancer was terminated; resul…
-
CLINICAL_TRIALS trial_result · 2019-11-20Clinical Trial Update: TARCEVA (Erlotinib) in Combination With Chemoradiation in Patients With Stage IIIA/B Non-Small Cell Lung Cancer (NSCLC) [Phase 2]
A Phase 2 clinical trial evaluating TARCEVA (erlotinib) in combination with chemoradiation for patients with stage IIIA/B non-small cell lun…
-
CLINICAL_TRIALS trial_result · 2019-11-19Clinical Trial Update: Adjuvant Cisplatin and Docetaxel in Non Small Cell Lung Cancer [Phase 2]
Phase 2 clinical trial update evaluating adjuvant cisplatin and docetaxel in non-small cell lung cancer has completed.
-
CLINICAL_TRIALS trial_result · 2019-11-15Clinical Trial Update: A Phase II Study of Fruquintinib in Combination With Gefitinib in Patients With Advanced Non-small Cell Lung Cancer [Phase 2]
A Phase II trial evaluating fruquintinib in combination with gefitinib for advanced non-small cell lung cancer has completed.
-
CLINICAL_TRIALS trial_result · 2019-11-15Clinical Trial Update: Efficacy and Safety Study of Anlotinib With Pembrolizumab in Adults With Programmed Cell Death-Ligand 1 (PD-L1)-Positive Treatment-naïve Non-small Cell Lung Cancer [Phase 2]
Phase 2 trial evaluating anlotinib in combination with pembrolizumab for PD-L1–positive, treatment-naïve non-small cell lung cancer.
-
CLINICAL_TRIALS trial_result · 2019-11-12Clinical Trial Update: Phase II Study of Pembrolizumab After Curative Intent Treatment for Oligometastatic Non-Small Cell Lung Cancer [Phase 2]
Phase II study evaluating pembrolizumab after curative-intent treatment for oligometastatic non-small cell lung cancer has completed, with r…
-
CLINICAL_TRIALS trial_result · 2019-11-12Clinical Trial Update: An Open Label Study in Patients With Advanced NSCLC With ABI-007(Abraxane) in Combination With Carboplatin [Phase 2]
Phase 2 open-label study of ABI-007 (Abraxane) plus carboplatin in advanced non-small cell lung cancer has completed.
-
CLINICAL_TRIALS trial_result · 2019-11-12Clinical Trial Update: Cancer Associated Thrombosis and Isoquercetin (CATIQ) [Phase 2, Phase 3]
Phase 2/3 clinical trial update for Cancer Associated Thrombosis and Isoquercetin (CATIQ) completed with posted results in 2019.
-
CLINICAL_TRIALS trial_result · 2019-11-08Clinical Trial Update: Gefitinib in Combination With Anlotinib or Placebo in Previously Untreated EGFR-mutant NSCLC [Phase 3]
Phase 3 trial assessing gefitinib with anlotinib or placebo in newly diagnosed EGFR-mutant non-small cell lung cancer.